RxDoctor Payments Data

Dania Verdecia

Adult Health · Miami, FLNPI 1003042581

Payments from drug & device makers

$984in general payments, 2019–2025

Across 42 payments — averaging $23.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$324
  • Amgen$158
  • GSK$135
  • Johnson & Johnson$103
  • Novo Nordisk$85
  • Boehringer Ingelheim$50
  • plus $128 from 6 others

What the payments were for

  • Food & beverage$984100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$984 in reported general payments places this provider in the 60th percentile of 2,237 adult health providers in Florida.

See all adult health providers in Florida

Medicare billing

Part B allowed, 2024
$9,481
Medicare patients
32
Services billed
240

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban83$91,973
OzempicSemaglutide58$58,330
MounjaroTirzepatide42$45,168
FarxigaDapagliflozin Propanediol37$36,133
JardianceEmpagliflozin18$27,393
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$24,444
LinzessLinaclotide25$22,787
TrulicityDulaglutide20$19,405
JanumetSitagliptin Phos/Metformin Hcl16$18,164
XareltoRivaroxaban24$14,316
Breo ElliptaFluticasone/Vilanterol25$10,116
VascepaIcosapent Ethyl20$9,658
Sildenafil Citrate15$5,295
Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro20$4,559
SynthroidLevothyroxine Sodium63$4,460

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$46$64,57362 claims
Novo NordiskOzempic$85$58,33058 claims
AstraZenecaFarxiga, Crestor$324$39,12648 claims
GSKTrelegy Ellipta, Breo Ellipta$135$34,56062 claims
Boehringer IngelheimJardiance$50$27,39318 claims
AbbVieLinzess, Synthroid$22$27,24788 claims
Johnson & JohnsonXarelto$103$14,31624 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,237 adult health providers in Florida.

Other adult health in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →